{"id":2753,"date":"2026-08-28T10:00:00","date_gmt":"2026-08-28T14:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2753"},"modified":"2026-08-28T16:38:10","modified_gmt":"2026-08-28T20:38:10","slug":"ps127-compounds-expose-an-aml-redox-vulnerability","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2753","title":{"rendered":"PS127 Compounds Expose an AML Redox Vulnerability"},"content":{"rendered":"

Institutions:<\/strong> Rice University \/ MD Anderson Cancer Center · Compound Class:<\/strong> PS127 Series · Indication:<\/strong> Acute Myeloid Leukemia · Stage:<\/strong> Preclinical (Ex Vivo) · Date:<\/strong> August 28, 2026<\/p>\n

\"20260828_Rice_MD_Anderson_PS127_Technology_and_Modalities\"<\/p>\n

Summary<\/h4>\n

Researchers at Rice University and MD Anderson Cancer Center identified a class of PS127 compounds through a function-based cheminformatic screen that induce autophagy, disrupt redox homeostasis via glutathione reductase, and trigger apoptosis in acute myeloid leukemia cells, with early evidence of synergy alongside existing AML therapies.<\/p>\n

What Happened<\/h4>\n

A screen of approximately 4.2 million structures yielded 93 hits, 81 of them PS127-related and 12 structurally distinct. Lead compounds showed submicromolar CC50 potency in MOLM-13 AML cells and better selectivity in normal PBMCs and rat cardiomyocytes than in AML cells. Synergy was observed in combination with midostaurin, venetoclax, and doxorubicin. All data reported are ex vivo or in vitro; no in vivo animal data have been generated.<\/p>\n

Deep Analysis<\/h4>\n

The redox-vulnerability mechanism, targeting glutathione reductase to disrupt AML cells’ antioxidant defenses, is differentiated from mainstream AML targets such as FLT3, BCL-2, and IDH1\/2. Funneling 4.2 million screened structures down to 12 structurally distinct hits reflects a genuinely early discovery-stage program. Combination synergy with approved agents including midostaurin and venetoclax is encouraging for eventual combination-regimen positioning, but the complete absence of in vivo data means pharmacokinetics, tolerability, and efficacy in a living system remain entirely unknown.<\/p>\n

Company and Product Background<\/h4>\n

This is academic, institution-led discovery research rather than a company-sponsored program. Translation to a clinical candidate would require a pharmaceutical or biotech partner, in vivo validation, and IND-enabling studies.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Screen Scale<\/td>\n~4.2M structures screened, 93 hits, 12 distinct PS127-related compounds<\/td>\n<\/tr>\n
Potency<\/td>\nSubmicromolar CC50 in MOLM-13 AML cell line<\/td>\n<\/tr>\n
Selectivity<\/td>\nImproved selectivity in PBMCs and rat cardiomyocytes vs AML cells<\/td>\n<\/tr>\n
Combination Data<\/td>\nSynergy with midostaurin, venetoclax, doxorubicin (ex vivo)<\/td>\n<\/tr>\n
Development Stage<\/td>\nPreclinical, ex vivo\/in vitro only; no in vivo data<\/td>\n<\/tr>\n
Signal Type<\/td>\nEarly academic discovery research<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A differentiated redox-vulnerability mechanism with submicromolar potency, favorable selectivity margins, and combination synergy with standard-of-care AML agents represents a scientifically credible new angle on a disease with persistent unmet need in relapsed and refractory settings.<\/p>\n

Bear case:<\/strong> The complete absence of in vivo data means the compounds have not yet been tested for basic pharmacokinetics, tolerability, or efficacy in a living organism, and academic hit-to-lead programs at this stage face a long and uncertain path before any clinical relevance can be assessed.<\/p>\n

InSilens Take<\/h4>\n

This is early, mechanistically interesting discovery science rather than a near-term clinical prospect; the next meaningful checkpoint would be in vivo proof-of-concept data, without which the redox-vulnerability approach remains a promising hypothesis rather than a validated lead.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 3\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> High on facts, Low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Researchers at Rice University and MD Anderson Cancer Center identified a class of PS127 compounds through a function-based cheminformatic screen that induce autophagy, disrupt redox homeostasis via glutathione reductase, and trigger apoptosis in acute…<\/p>\n","protected":false},"author":1,"featured_media":2764,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[76],"class_list":["post-2753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-myeloid-leukemia"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2753"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2753\/revisions"}],"predecessor-version":[{"id":2773,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2753\/revisions\/2773"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2764"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}